BK vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BK exhibits stable financial health with a Piotroski F-Score of 4/9 and an exceptional operational track record, beating earnings estimates in nearly every quarter over the last 25 periods. While the current price of $131.96 trades at a premium to the Graham Number ($97.73), it remains significantly discounted relative to its growth-based intrinsic value of $218.3. Strong YoY earnings growth of 30.5% and a conservative dividend payout ratio of 27.03% suggest sustainable long-term expansion. The primary divergence is a bearish technical trend score despite strong recent price performance.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
BK vs JPM: Head-to-Head Comparison
This page compares The Bank of New York Mellon Corporation (BK) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.